Network Immunology Announces MAB3™


Network Immunology, a preclinical stage biotech company focused on novel treatments to prevent and treat automimmune conditions and cancer, announces a new monoclonal antibody-based technology. Network Immunology’s Chief Scientist, Geoffrey W. Hoffmann, has discovered a way to make a kind of antibody for humans that has been shown in studies with mice to be intimately associated with the suppression of the immune system. Network Immunology has filed a patent application for the use of this kind of antibody in the prevention and treatment of autoimmunity.

Corporate Updates

Captcha Image